Continuous Glucose Monitors Could Cut Diabetes Death Risk by 40%

A simple gadget could save millions of Americans with diabetes from dying. A new study suggests that wearing a continuous glucose monitoring device might lower mortality risk for those living with type 2 diabetes. More than 38 million people in the United States suffer from this condition. Researchers tracked diabetics taking basal insulin, which is long-acting insulin. After one year of using a continuous glucose monitor, these patients faced a 44 percent drop in death risk from any cause. Two years into use, that number fell to 35 percent lower. The data also pointed to fewer cardiovascular events like strokes or heart attacks.

This CGM is a small wearable tech. It constantly tracks sugar levels instead of relying on single-point finger-stick tests. A tiny sensor goes under the skin on the arm or abdomen. It measures fluid around cells rather than blood directly. Readings stream to a smartphone screen immediately. Users can watch current glucose numbers and follow daily spikes and dips. They can see how food or drinks alter their sugar levels in real time.

The team shared these results at the European Association for the Study of Diabetes annual meeting in Italy. Experts note this is the first proof linking CGMs to lower death risks in type 2 diabetics on basal insulin. Type 2 diabetes means the body struggles to use insulin properly. The pancreas makes this hormone to shuttle sugar into cells for energy. Genetics, lifestyle choices, and health issues drive this disease. Cells resist insulin, so the pancreas pumps out more of it to cope. Eventually the organ cannot keep up. Glucose piles up in blood streams and stays too high. High blood sugar damages vessels and nerves over time. It can cause blindness, kidney failure, heart disease, or stroke.

For type 2 diabetics, a CGM serves as a vital tool for control. Constant tracking shows how levels fluctuate hour by hour. Factors like eating, moving, and taking meds become clear. Seeing this data helps patients manage their condition better. The urgency remains high because so many Americans face these risks today.

It serves as an early warning system for dangerous blood sugar spikes or drops while helping doctors and patients judge how well a treatment plan is holding up. To truly grasp how continuous glucose monitoring affects mortality risk, researchers from Abbott dug into their own data using Truveta. This massive database holds anonymized electronic health records for more than 140 million Americans. They analyzed the odds of dying from any cause plus macrovascular events like heart attacks, heart failure, stroke, and peripheral artery disease in type 2 diabetes patients on basal insulin between 2017 and 2024.

The trial pitted nearly 14,000 people wearing CGMs against a matching group of 14,000 non-users. The study accounted for age, sex, ethnicity, how long they had lived with diabetes, other health conditions, medication use, and blood sugar control levels. Across the board, users saw a lower risk of death. At one year mark, only 1.2 percent of CGM users died versus 2.1 percent of those without devices. By two years out, the numbers shifted slightly but stayed in favor of monitoring: 2.1 percent for users and 3.3 percent for non-users.

Major heart issues also dropped significantly among those wearing monitors. The chance of a macrovascular event was 26 percent lower at one year. Repeat events fell even further, down 35 percent after twelve months and 36 percent after two years. Hospitalizations due to heart failure saw an even steeper drop. At the one-year check-in, rates were 54 percent lower for users compared to non-users. By the two-year mark, that advantage held at 47 percent.

Professor Jochen Seufert from the University Hospital of Freiburg in Germany led the project. He told reporters their study shows CGMs can genuinely change long-term health outcomes for people with type 2 diabetes who need insulin and might lower early death risks. These results build a stronger argument for widening access to this technology for anyone on basal insulin therapy who could benefit. It remains vital that we push for fair and equitable access to diabetes tools alongside the training needed to use them well so no one gets left behind.

Insurance often covers these devices for people with diabetes, meaning most patients pay between $0 and $75 a month. Without coverage, the price jumps to hundreds of dollars.